Apr 7, 2009 - Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application for Silenor (doxepin) for the treatment of insomnia.
The details can be read here.
No comments:
Post a Comment